Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate, atacicept, is a fusion protein that targets B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which are members of the tumor necrosis factor (TNF) superfamily. Atacicept has the potential to address a broad range of autoimmune and inflammatory diseases, including primary IgA nephropathy, a rare kidney disease with no approved therapies. Vera Therapeutics is headquartered in San Bruno, California.